FDA Declines Regeneron's Lymphoma Therapy
This is a Regeneron news story, published by Yahoo, that relates primarily to FDA news.
Regeneron news
For more Regeneron news, you can click here:
more Regeneron newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo news
For more news from Yahoo, you can click here:
more news from YahooAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
FDA. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest regulatory decision news, Regeneron news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
regulatory approvalReuters
•US FDA declines to approve Regeneron's blood cancer therapy
79% Informative
Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma.
FDA said sole issue identified for approval is related to findings from a pre-approval inspection at a third -party manufacturer.
Regeneron said it is committed to working closely with the third party manufacturer and the health regulator.
VR Score
88
Informative language
96
Neutral language
28
Article tone
formal
Language
English
Language complexity
80
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links